Τίτλος:
Combination chemotherapy with cisplatin, etoposide and irinotecan in
patients with extensive small-cell lung cancer: A phase II study of the
Hellenic Co-operative Oncology Group
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objective: The purpose of this study was to evaluate the efficacy and
toxicity of cisplatin, etoposide and irinotecan as first-tine treatment
in patients with extensive small-cell lung cancer (E-SCLC).
Patients and methods: Chemo-naive adult patients with a performance
status (PS) of 0-2 and adequate organ function were eligible. Patients
received cisplatin 20 mg/m(2) i.v. daily for three consecutive days,
etoposide 75mg/m(2) i.v. daily for three consecutive days and irinotecan
120mg/m(2) i.v. on day 2, every 21 days for six to eight cycles.
Administration of G-CSF was given in the presence of febrile neutropenia
and as a 5-day prophylaxis around the recorded nadir day in patients who
developed grades 3-4 neutropenia.
Results: Fifty-six patients were assessable. The median age was 62.2
years; 96.4% had PS 0-1, 33.5% had >3 metastatic sites. The overall
response rate was 80.4% with 8 (14.3%) patients achieving a complete
response. The median time to tumor progression was 7.8 months [95% Cl
confidence interval (Cl), 7.1-8.6 months] with a median survival of 15.1
months [95% Cl, 9.7-20.5 months] and 1-year survival rate of 56.5%.
One patient died from toxicity. Grades 3-4 neutropenia occurred in
37.5% of patients, grades 3-4 thrombocytopenia occurred in 10.9% of
patients and 11 (19.6%) patients developed febrile neutropenia. Grades
3-4 non-hematological toxicities were primarily nausea-vomiting 3.6%,
diarrhea 7.1% and fatigue 3.6%.
Conclusion: This study strongly suggests that cisplatin, etoposide and
irinotecan combination is very effective for the treatment of E-SCLC
with good safety profile. The triplet regimen currently seems a
promising regimen and has to be further explored in phase III trials.
(c) 2007 Elsevier Ireland Ltd. All rights reserved.
Συγγραφείς:
Pectasides, D.
Samantas, E.
Fountzilas, G.
Briasoulis, E.
and Kosmidis, P.
Skarlos, D.
Dimopoulos, M. A.
Kalofonos, H.
P.
Economopoulos, T.
Syrigos, K.
Περιοδικό:
Translational Lung Cancer Research
Εκδότης:
Elsevier Ireland Ltd
Λέξεις-κλειδιά:
cisplatin; etoposide; irinotecan; extensive small-cell lung cancer
DOI:
10.1016/j.lungcan.2007.06.027
